engleski

Clinical Applicability of Tumor Marker Cyfra 21-1 in NSCLC Patients during a 20 Months Period

The serum level of cyfra 21-1 tumor marker has been longitudinally followed up in 274 patients with NSCLC lung cancer after surgery and chemotherapy, five times during a 20 month period (before the therapy, 1, 4, 10, 16 and 20 months afterthe therapy). After the surgical treatment of 46 patients with squamous cell carcinoma and 52 with adenocarcinoma chemotherapy was applied. A significant decrease of tumor marker cyfra 21-1 toward the population values was observed 1 to 3 months after the therapy. In 34 stage IV patients taxol+cisplatinum or taxol+gemcitabine therapy was applied. In this subgroup the level of cyfra 21-1 fell in 20 patients, while in 9 it increased and in 5 it remained the same. In 46 patients the increase of the cyfra 21-1 serum level was observed 10 to 20 months after the therapy, which is 1 to 3 months before other methods proved the relapse of the disease. According to this result we can conclude that the follow up of tumor marker cyfra 21-1 in every patient after therapy is very important, because the increase of its concentration shows possible local relapse of the disease earlier than using other diagnostic methods. We can also conclude that the tumor marker cyfra 21-1 is necessary in postoperative monitoring in patients with NSCLC, because the increase of its level is a very good indicator to detect local relapse.

cyfra21-1; lung cancer; tumor markers; anthropology; population genetics

nije evidentirano